Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?

The treatment strategy for metastatic renal cell carcinoma (mRCC) has evolved with the emergence of anti-angiogenic drugs, in particular tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptor (VEGFR) and immune checkpoint inhibitors (ICIs). Both treatment options...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: R. A. Gafanov, A. G. Dzidzaria, I. B. Kravtsov, S. V. Fastovets
Formato: Artigo
Idioma:Russo
Publicado em: ABV-press 2020-09-01
Colecção:Onkourologiâ
Assuntos:
angiogenesis
combination
immune checkpoint inhibitor
immunotherapy
renal cell carcinoma
tyrosine kinase inhibitor
Acesso em linha:https://oncourology.abvpress.ru/oncur/article/view/1360
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados